An interventional efficacy and safety, phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/Ritonavir compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at low risk of progressing to severe illness

Brief summary: The primary hypothesis to be tested is whether or not there is a difference in time to sustained alleviation of all targeted COVID-19 signs and symptoms through Day 28 between PF-07321332/ritonavir and placebo.